![PDF) P721 A switch in the prevalence ratio of Crohn's disease vs. ulcerative colitis in Israel between 2003 and 2015 – a report from the epi-IIRN group PDF) P721 A switch in the prevalence ratio of Crohn's disease vs. ulcerative colitis in Israel between 2003 and 2015 – a report from the epi-IIRN group](https://i1.rgstatic.net/publication/313464751_P721_A_switch_in_the_prevalence_ratio_of_Crohn's_disease_vs_ulcerative_colitis_in_Israel_between_2003_and_2015_-_a_report_from_the_epi-IIRN_group/links/5aa1797daca272d448b371f7/largepreview.png)
PDF) P721 A switch in the prevalence ratio of Crohn's disease vs. ulcerative colitis in Israel between 2003 and 2015 – a report from the epi-IIRN group
![14th Congress of ECCO - Congresses & Events - Events - Events & Newsroom - The European Society of Pathology 14th Congress of ECCO - Congresses & Events - Events - Events & Newsroom - The European Society of Pathology](https://www.esp-pathology.org/_Resources/Persistent/e63342e3c9fd510184d2343b4232c16550758458/MASTER_ECCO%2719%20Web%20banner_150x100%20%28002%29.jpg)
14th Congress of ECCO - Congresses & Events - Events - Events & Newsroom - The European Society of Pathology
![PDF) P586 A novel approach to the implementation of biosimilar infliximab CT-P13 for the treatment of IBD utilising therapeutic drug monitoring: the Edinburgh experience PDF) P586 A novel approach to the implementation of biosimilar infliximab CT-P13 for the treatment of IBD utilising therapeutic drug monitoring: the Edinburgh experience](https://i1.rgstatic.net/publication/313468929_P586_A_novel_approach_to_the_implementation_of_biosimilar_infliximab_CT-P13_for_the_treatment_of_IBD_utilising_therapeutic_drug_monitoring_the_Edinburgh_experience/links/5b2658faa6fdcc697469f7a7/largepreview.png)
PDF) P586 A novel approach to the implementation of biosimilar infliximab CT-P13 for the treatment of IBD utilising therapeutic drug monitoring: the Edinburgh experience
![Y-ECCO on Twitter: "Peter Irving bravely tackling difficult realities of #ibd healthcare in cost limited times. Azathioprine monotherapy? Biosimilars? #ecco2017… https://t.co/7QyzI6ikR8" Y-ECCO on Twitter: "Peter Irving bravely tackling difficult realities of #ibd healthcare in cost limited times. Azathioprine monotherapy? Biosimilars? #ecco2017… https://t.co/7QyzI6ikR8"](https://pbs.twimg.com/media/C4yzn03WEAMmMjc.jpg:large)
Y-ECCO on Twitter: "Peter Irving bravely tackling difficult realities of #ibd healthcare in cost limited times. Azathioprine monotherapy? Biosimilars? #ecco2017… https://t.co/7QyzI6ikR8"
![Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease | SpringerLink Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10620-019-06036-0/MediaObjects/10620_2019_6036_Fig1_HTML.png)
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease | SpringerLink
![Amsterdam RAI EACCME applied Register online at Inflammatory Bowel Diseases 2016 IBD innovations driving clinical decisions. - ppt download Amsterdam RAI EACCME applied Register online at Inflammatory Bowel Diseases 2016 IBD innovations driving clinical decisions. - ppt download](https://slideplayer.com/77/12804754/big_thumb.jpg)
Amsterdam RAI EACCME applied Register online at Inflammatory Bowel Diseases 2016 IBD innovations driving clinical decisions. - ppt download
![12th Congress of ECCO - Congresses & Events - Events - Events & Newsroom - The European Society of Pathology 12th Congress of ECCO - Congresses & Events - Events - Events & Newsroom - The European Society of Pathology](https://www.esp-pathology.org/_Resources/Persistent/ac53b796218c5b837763c09492b2107fa2791497/170907_v2_ECCO%2717%20Web%20banner_150x100.jpg)